

DESCRIPTION

Species Reactivity	Human/Mouse/Rat
Specificity	Detects human, mouse, and rat DGCR2 in Western blots. Detects human DGCR2 in direct ELISAs.
Source	Monoclonal Mouse IgG _{2B} Clone # 1019908
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Chinese Hamster Ovary cell line CHO-derived human DGCR2 Glu22-Ala349 Accession # P98153
Conjugate	Alexa Fluor 405 Excitation Wavelength: 405 nm Emission Wavelength: 421 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

DiGeorge Syndrome Critical Region 2 (DGCR2), also known as IDD, DGS-C, LAN, and SEZ-12, is an adhesion receptor protein located on the long arm of chromosome 22 (1). The DGCR2 gene encodes an integral membrane protein, consisting of an extracellular domain, a single transmembrane region and a cytoplasmic tail (1). The mature extracellular domain (ECD) of DGCR2 contains both a C-type lectin domain and a cysteine-rich region similar to that of the low density lipoprotein receptor (LDLR) (1, 3). The mature ECD of human DGCR2 shares 93% and 92% amino acid sequence identity with mouse and rat, respectively. DGCR2 is expressed during neurodevelopment in human brain tissues (3). Deletion of the 22q11.2 region results in an extremely variable disorder called 22q11.2 deletion syndrome, with a phenotype ranging from very mild symptoms to severe intellectual disability, facial dysmorphism, heart defects, and urogenital abnormalities (4). Recent studies suggest that DGCR2 regulates critical steps of early cortico-genesis possibly through a Reelin-dependent mechanism. Deletion of DGCR2 has a pathogenic impact on cortical formation by reducing protein expression level, and it plays a critical role in vulnerability to schizophrenia (5). Furthermore, expression of DGCR2 together with USP18 gene may serve as a prognostic marker for muscle invasive bladder cancer survival in patients (5).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.